Congress gains leverage over global anti-doping body through conditional funding

What it does

This bill gives the U.S. Office of National Drug Control Policy (ONDCP) the power to annually assess whether the World Anti-Doping Agency (WADA) has fair governance, independent decision-making, and adequate U.S. representation. If WADA fails these tests, the ONDCP can withhold U.S. membership dues (up to the full amount), must report to Congress on barriers to U.S. participation, and must submit spending plans before paying any dues. The bill essentially makes U.S. funding conditional on WADA meeting specific governance and representation standards.

Why we flagged it

The bill's core mechanism is conditional funding tied to governance standards and mandatory congressional reporting. It is fundamentally about U.S. leverage over WADA and increased transparency to Congress, not about anti-doping policy itself.

What the text implies

• Withholding dues could fragment global anti-doping enforcement if other nations follow suit or if WADA loses operational capacity, potentially harming clean athletes worldwide.
• The bill does not define what constitutes 'fair representation' or 'credible governance'—these are subjective standards that ONDCP will apply annually, creating potential for politicization of anti-doping policy.
• Mandatory spending plans and congressional reporting may slow U.S. funding disbursement and create bureaucratic friction in international anti-doping coordination.
• The bill empowers ONDCP (a domestic drug-policy agency) to make determinations about international sports governance, potentially conflating drug policy with Olympic/athletic governance.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill strengthens U.S. leverage over an international anti-doping body and increases congressional oversight of how U.S. dues are spent—a transparency and accountability gain. However, withholding dues could weaken global anti-doping enforcement and harm amateur athletes worldwide who depend on WADA's work, creating a potential public-health trade-off.

Named in the bill

Office of National Drug Control Policy (ONDCP), World Anti-Doping Agency (WADA), U.S. Anti-Doping Agency (USADA), U.S. Olympic and Paralympic Committee, Athletes' Advisory Council, International Olympic Committee (IOC), International Paralympic Committee (IPC), Senate Committee on Commerce, Science, and Transportation, House Committee on Energy and Commerce, Senate Committee on Appropriations, House Committee on Appropriations

Where it stands

6 cosponsors: 4 Democrats, 2 Republicans.

• Jan 23, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jan 23, 2025 — Referred to Senate Committee on Commerce, Science, and Transportation · Congress.gov: “Read twice and referred to the Committee on Commerce, Science, and Transportation”
• Jun 25, 2025 — Reported out of committee · Congress.gov: “Committee on Commerce, Science, and Transportation. Ordered to be reported with an amendment in the nature of…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Dec 2025 to Dec 2025. Those filings disclosed $40,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Marsha Blackburn, the sponsor, reported $133,620 in PAC receipts in the 2026 cycle.

• United States Olympic and Paralympic Committee — $40,000 on 1 filing

Lobbying Disclosure Act filings through Jan 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.